PMID- 37868870 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231116 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 15 IP - 9 DP - 2023 Sep 28 TI - Impact of anesthetic factors on prognosis of patients with non-small cell lung cancer after surgery. PG - 4869-4884 LID - 10.21037/jtd-22-1812 [doi] AB - BACKGROUND: Nowadays, the influence of anesthesia management on the prognosis of cancer patients has been widely concerned. The goal of this study is to assess the association between anesthetic factors and the prognosis of patients with non-small cell lung cancer (NSCLC) after surgery. METHODS: Patients with NSCLC who underwent surgery from January 1, 2006, to December 31, 2009 were selected. Cox proportional hazards model and Logistic regression analysis model were used to screen the independent predictors of prognosis of patients. The primary endpoint was postoperative overall survival (OS), and the secondary endpoint was postoperative recurrence-free survival (RFS) and postoperative pulmonary complications (PPCs). RESULTS: A total of 588 patients were included into the final analysis. The overall RFS was 4.4 [interquartile range (IQR), 1.1-10.1] years, and the OS was 6.2 (IQR, 2.4-10.2) years. Age >/=60 years, advanced tumor stage, and maximal tumor size >3 cm were associated with shortened survival, whereas high BMI grade, mediastinal lymph node dissection, perioperative fentanyl equivalents >28.2 microg/kg, and high tumor grade were associated with prolonged survival (P<0.05); perioperative glucocorticoid administration delayed recurrence (P<0.05); advanced tumor stage and perioperative fentanyl equivalents >28.2 microg/kg were associated with an increased PPCs risk (P<0.05). CONCLUSIONS: The findings from this study revealed that perioperative anesthetic factors may impact the prognosis of patients with NSCLC after surgery. Perioperative opioid and glucocorticoid exposure were independent predictors for outcomes. However, perioperative fentanyl equivalents over 28.2 microg/kg seemed to be beneficial to OS, but contribute to the occurrence of PPCs. CI - 2023 Journal of Thoracic Disease. All rights reserved. FAU - Zhu, Wenzhi AU - Zhu W AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Anesthesiology, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Li, Shuang AU - Li S AD - Department of Anesthesiology, Chines PLA General Hospital & Medical School, Beijing, China. FAU - Ji, Xinqiang AU - Ji X AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of medical record statistics, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Tan, Hongyu AU - Tan H AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Anesthesiology, Peking University Cancer Hospital & Institute, Beijing, China. LA - eng PT - Journal Article DEP - 20230621 PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 CIN - J Thorac Dis. 2023 Oct 31;15(10):5272-5274. PMID: 37969287 PMC - PMC10586941 OTO - NOTNLM OT - Anesthetic factor OT - non-small cell lung cancer (NSCLC) OT - opioid OT - prognosis COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-1812/coif). The authors have no conflicts of interest to declare. EDAT- 2023/10/23 06:46 MHDA- 2023/10/23 06:47 PMCR- 2023/09/28 CRDT- 2023/10/23 04:44 PHST- 2022/12/16 00:00 [received] PHST- 2023/06/02 00:00 [accepted] PHST- 2023/10/23 06:47 [medline] PHST- 2023/10/23 06:46 [pubmed] PHST- 2023/10/23 04:44 [entrez] PHST- 2023/09/28 00:00 [pmc-release] AID - jtd-15-09-4869 [pii] AID - 10.21037/jtd-22-1812 [doi] PST - ppublish SO - J Thorac Dis. 2023 Sep 28;15(9):4869-4884. doi: 10.21037/jtd-22-1812. Epub 2023 Jun 21.